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Celiac disease (CD) is a permanent intolerance to dietary protein, gluten, from wheat rye 
and barley. It occurs in about 1% worldwide population, in genetically predisposed 
individuals bearing human leukocyte antigen (HLA) DQ2/DQ8. Although gut epithelial cell 
stress and the innate immune activation are responsible for the breaking oral tolerance to 
gliadin, the gluten component, the exact mechanisms through which gliadin can stimulate 
CD onset are still unclear. Here I show how is important to identify in vivo preclinical models 
of CD to study its pathogenesis, at molecular level. 
The increasing prevalence of positive serological marker of CD in Cystic Fibrosis (CF) 
affected patients let to the hypothesis of a link between the two disorders. Results from my 
studies indicate that CFTR is potentially involved in the pathogenesis of CD, with gliadin 
peptides inhibiting CFTR activity and expression. 
To date, the only treatment available for CD is a long-term gluten-free diet. Several 
evidences show that an altered composition of the intestinal microbiota (dysbiosis) could 
play a key role in the pathogenesis of CD, through the modulation of intestinal permeability 
and the regulation of the immune system. Indeed, although further studies are still required 
to unveil the molecular mechanisms, results reported in the present work clearly indicate 
that rebalancing the gut microbiota composition by probiotics administration might represent 

































Celiac Disease is a complex immune-mediated chronic disease characterized by 
strong inflammatory reactions to dietary gluten intake by genetically predisposed individuals, 
affecting the intestinal barrier.  
 
1. THE INTESTINAL BARRIER 
The intestinal mucosal barrier, also known as intestinal barrier, has a crucial role in the 
defence from pathogens and from potentially harmful substances present in the 
environment. The intestinal barrier is composed by physical, biochemical, and immune 
elements highly organized by the intestinal mucosa. 
 
1.1 STRUCTURE AND FUNCTIONS 
The central component of the intestinal barrier is represented by the epithelial layer, which 
provides physical separation between the lumen and the body (figure 1). The secretion of 
several molecules in the lumen help the barrier function on the extraepithelial side, and a 
diversity of immune cells provide protection below the epithelial layer. Immune cells, 
intestinal microbiota and anti-microbial peptides have the main role in maintaining the 
intestinal barrier function (Takiishi et al., 2017). In the gastrointestinal tract (GI), the mucus 
barrier forms a protective layer on the apical surface of the intestinal epithelium to avoid 
adherence and subsequent invasion by external pathogens. Moreover, the mucus lubricates 
food and digestive secretion, protecting the intestinal epithelium from potential damages 




Figure 1. Structure of the intestinal barrier. The intestinal barrier is made of cellular and 
extracellular elements. The cellular fraction is composed by intestinal epithelium and the 
underlying lamina propria, which contains DCs, macrophages, intraepithelial lymphocytes 
(IEL), T regulatory cells (T Regs), TCD4+ lymphocytes (T CD4), B lymphocytes, and plasma 
cells. The extracellular part is made of a mucus layer produced by Goblet cells, AMPs 
secreted by Paneth cells, and sIgA dimers released by plasma cells. DCs, dendritic cells; 
AMPs, antimicrobial peptides; sIgA, secretory Immunoglobulin A. (De Santis et al., 2015) 
 
1.2 MUCUS 
Mucus forms a layer, or layers in the colon, gather the epithelium of the GI. It prevents large 
particles from contacting the epithelial cell but allowing the passage of small molecules. The 
mucus makes easier the passage of the luminal contents along the length of the gut, protects 
the epithelial cells from digestive enzymes, and prevents the direct contact between 
microorganisms and epithelial cells. Mucus is secreted by goblet cells and is formed of 
approximately 95% water. One of the mainly components of the mucus are mucins, which 
are glycosylated big proteins rich in serine and threonine (Bansil & Turner, 2006). 
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Complementary to that, lysozyme digest bacterial cell wall components (Nakimbugwe et al., 
2006; Ragland & Criss, 2017). Immunoglobulins, specifically secreted IgA, contribute to 
mucosa homeostasis since lack of IgG leads to protein losing-enteropathy (Hooper et al., 
2012). Grow factors such as transforming growth factor beta, are involved in growth, 
maintenance, repair and regulatory function in the epithelium (Scherf et al., 2005). 
 
1.3 THE INTESTINAL EPITHELIUM  
The epithelium covering of the intestinal wall represents the most important component of 
the intestinal barrier. Crucial for having a real barrier is the control of the paracellular 
pathway. Indeed, in addition to its protective function, the intestinal epithelium also controls 
the selective uptake of beneficial ions, nutrients, and other substances from the lumen. 
In this single cell layer, cells are attached to each other by the apical junctional complex 
which seals the paracellular space to the intestinal lumen. Stem cells present in the crypts 
are responsible for the constant renewal of this epithelium, through cell division, maturation 
and cell migration.  
The predominant cells in the small intestine, are enterocytes, devoted to the absorption of 
nutrients, while goblet cells are the main mucus-secreting cells, and with Paneth cells 
playing a crucial role in the host defense against bacteria and in the regulation of the 
microbiota, mainly though the production and release of defensins, members of a large 
family of cationic antimicrobial peptides representing an essential element of innate 
immunity (Pasupuleti et al., 2012). M cells are a subset of epithelial cells highly specialized 
for antigen sampling. In fact, they transport antigens and intact microorganisms from the gut 
lumen to the lamina propria, in order to present them to immune cells and thus igniting the 
immune response (Kucharzik et al., 2000). Finally, Tuft cells monitor the intestinal lumen, 
and in case of local injury or bacterial infection, they transmit signals to immune cells in the 
underlying epithelia, activating the immune response (Ting & von Moltke, 2019).  
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The ‘selective barrier’ activity carried out by intestinal epithelium rely on two major pathways: 
the transcellular and paracellular pathways. The former is involved in the transport and 
absorption of nutrients including amino acids, small peptides, fatty acids, vitamins, short-
chain fatty acids (SCFA) and sugars, through epithelial cells (Den Besten et al., 2013).This 
is generally regulated by selective transporters and channels located on the apical and 
basolateral surface of epithelial cells. However, larger antigens (>600Da), such as dietary 
peptides, can also cross the barrier through the transcellular transport, mediated by 
enterocytes and consisting in coupled endocytosis (on the luminal side) and exocytosis (on 
the body side). Released antigens can then interact with immune cells (Ménard et al., 2010). 
Importantly, this process is thought to be critical for the oral tolerance (Pabst & Mowat, 
2012). Larger antigenic molecules, such as microbial components, may also cross the 
epithelial barrier through M cells, which are located in the epithelium of Peyer’s patches or 
isolated lymphoid follicles (ILF) (Pabst & Mowat, 2012). Therefore, the uptake of luminal 
antigens through M cells and absorptive enterocytes plays a key role in maintaining the gut 
homeostasis. 
 
Figure 2. Intestinal epithelial barrier. (Chaithanya et all 2018) 
11 
 
1.4 INTESTINAL CELL JUNCTIONS  
 
Figure3. TJ structure. Tight junctions are the mainly mechanism which regulates whether 
the epithelium is tight or leaky. Tight junction permeability is primarily regulated by proteins 
in the claudin family that form a seal to both restrict paracellular diffusion and permit specific 
transport of ions between cells across the epithelial barrier. 
 
The barrier function of the intestinal epithelium mainly relays on the presence of specific 
cell-cell junctions occurring among epithelial cells, such as tight (TJ) and adherens junctions 
(AJ) (figure 3). TJs are located to the most apical part of the lateral epithelial cell membrane, 
which main functions were described as being a gate and a fence. In fact, they have the 
ability of selectively control the luminal components crossing the interepithelial space (gate 
function), and also to restrict lateral diffusion of membrane proteins as well as membrane 
lipids to either the apical or the basolateral compartment (fence). Main constituents of TJs 
include the transmembrane proteins occludins, the family of claudins and junctional 
adhesion molecules (JAM) (Citi, 2019). Although occludins were the first TJ component to 
be identified, their role remains somehow obscure, although they were reported to be 
involved in the regulation of paracellular permeability. On the contrary, claudins seem to be 
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the crucial component of TJ assuring the barrier function. Claudins also have functions in 
cytoskeleton organization, transport of vesicles and signaling pathways directly associated 
with scaffold proteins such as ZO-1 (Garcia-Hernandez et al., 2017). Alteration of the 
intestinal homeostasis is related to alterations in the expression of claudins. 
Claudin dysfunction may contribute to epithelial permeability disorder and more intestinal 
diseases. Indeed, over recent years, the importance of claudins in the pathogenesis of 
inflammatory bowel diseases (IBD) has gained focus and is being investigated. 
Proinflammatory cytokines-induced small molecule (e.g., ions and mannitol) channel 
disruption and cell detachment-induced large molecule (e.g., epidermal growth factor, EGF) 
leakage (DiGuilio et al., 2016). Thus, as barrier-forming proteins, dysregulated expression 
and redistribution of claudins may lead to increased intestinal permeability, susceptibility to 
gut infection and bowel symptoms of IBD patients (Chang et al., 2017).  
 
1.5 INTESTINAL IMMUNE SYSTEM 
The gut immune system is characterized by high plasticity, being highly and promptly 
reactive toward pathogens, while maintaining tolerance toward innocuous antigens, 
including dietary antigens and commensal bacteria. Antigen-specific immune responses are 
generated at sites of induction, including mesenteric lymph nodes (MLNs), Peyer’s patches, 
and ILF. Peyer’s patches are located in the submucosa of the small intestine, while ILF are 
found in the lamina propria of the small and large intestine. The lamina propria and 
epithelium make up the effector sites and here there is a large population of lymphoid cells 
(Pabst & Mowat, 2012). Specialized M cells are located in the epithelium overlaying Peyer’s 
patches, and are able to uptake the antigens and continuous sampling of luminal contents 
(Kobayashi et al., 2019). Antigens are then taken up by underlying antigen presenting cells 
(APCs), such as dendritic cells (DCs), which undergo maturation and present antigens to 
naïve CD4+ T cells, thus activating the antigen-specific T helper (figure 4). Interactions 
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between CD4+ T cells and B cells in the Peyer’s patches and MLN also results in the 
activation and expansion of B cells to become antibody-producing plasma cells. The local 
cytokine environment plays a key role in shaping the immune responses (figure 4). Following 
activation, CD4+ T cells and B cells move back to the lamina propria as effector cells or 
antibody-producing plasma cells. Other immune cells and phagocytes, such as 
granulocytes, are also found in the intestinal lamina propria. These cells, especially 
migratory DCs and macrophages, play an important role in the adaptative immune response. 
Other important immune cell are the intraepithelial lymphocytes (IELs), which are 
specialized effector T cells residing within the epithelial barrier. IELs are the first line of 
defense for invading pathogen, are also involved in maintaining barrier function, due to their 
direct contact with IECs and close proximity to luminal antigens (Van Wijk & Cheroutre, 
2010).This allows them to respond quickly to stress signals, thus representing an innate-like 
population of T cells (Gaudino & Kumar, 2019). IELs show cytolytic functions and are 
capable of producing pro-inflammatory cytokines in response to invading pathogens (figure 
4). However, IELs also have regulatory functions that promote barrier function and epithelial 














Figure 4. Immune system in the lamina propria of gut. Intestinal epithelial barrier is the 
first line of defense to prevent the pathogens invasion, including the epithelial TJ complexes, 
mucus layer, secretory immunoglobulin A, antimicrobial protein secretion by plasma cells, 
and Paneth cells. With regard to the innate immune response in intestine, neutrophils could 
be earlier recruited to inflammatory sites to clear the pathogens. Moreover, macrophages, 
dendritic cells (DCs), and innate lymphoid cells (ILCs) could sense antigens and then 
secrete cytokines or chemokines to regulate the inflammatory responses (adapted by M. 
Sun et al 2015). 
 
2. CELIAC DISEASE 
The intestinal immune system faces the lifelong challenge of identifying what is safe and 
what is not. Under physiological conditions, an efficient system guarantees correct tissue 
homeostasis and the capacity of suppressing inflammation and promoting oral tolerance to 
non-self-antigens such as those from diet or commensal microbes (Perrier & Corthésy, 
2011). However, the delicate equilibrium at the base of the tolerogenic response can be 
compromised by environmental triggers, such as viral infections (Bouziat et al., 2017) or 
intrinsic predisposing factors, leading to inappropriate immune and inflammatory responses. 
In this context, Celiac disease (CD) is an immune-mediated disorder characterized by an 
autoimmune enteropathy due to exposure to dietary proteins from wheat, rye and barley, 
occurring in 1% of individuals worldwide (Leonard et al., 2017). CD belongs to a spectrum 
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of gluten-related disorders (GRD), which also includes non-celiac gluten sensitivity (NCGS), 
dermatitis herpetiformis, and gluten ataxia. It also occurs in genetically predisposed 
individuals bearing the human leukocyte antigen (HLA) DQ2/DQ8. In a subset of genetically 
susceptible individuals, the ingestion of gluten proteins switches tolerance toward an 
adaptive immune response with an autoimmune component (Sollid & Jabri, 2013). There is 
a strong link between CD and autoimmunity given that 5%–10% of patients with diabetes 1 
type (T1D) develop CD, whereas, 15%–20% of CD patients have or will develop 
autoimmune diseases (Cosnes et al., 2008). 
 
2.1 CD DIAGNOSIS 
Early diagnosis of the disease in patients with atypical symptoms decreases the risk of 
serious complications such as intestinal lymphoma. Untreated CD may lead to 
osteopenia and infertility and may trigger other autoimmune diseases. Therefore, CD should 
be diagnosed as early as possible. The clinical spectrum of celiac disease is wide, including 
cases with either typical intestinal (e.g., chronic diarrhea, weight loss) or “atypical” 
extraintestinal (e.g., anemia, osteoporosis, neurological disturbances) features, and silent 
forms that are occasionally discovered because of serological screening (Figure 5).  
 
Figure 5. Schematic CD feature.  https://www.gutmicrobiotaforhealth.com/ 
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The typical jejunal damage associated with active celiac disease is characterized by villous 
atrophy (Figure 6), crypt hypertrophy, and increased intraepithelial lymphocyte count. The 
small intestinal biopsy is still considered a key investigation in the current guidelines of North 
American and European gastroenterological societies. 
Indeed, many individuals with celiac disease may have no symptoms and the disease is 
usually detected by serologic testing of celiac-specific antibodies, which is confirmed by 
duodenal mucosal biopsies. Both serology and biopsy should be performed on a gluten-
containing diet. In the serologic analysis the Immunoglobulin (Ig)A anti-gliadin (AGA), anti-
endomysial (EMA) and anti-tissue transglutaminase (TG2) antibodies are considered the 
best immunologic markers of CD. 
The treatment for celiac disease is primarily a gluten-free diet (GFD). 
 
Figure 6.  CD features. Villous atrophy (upper panel; beyongcelic.org); crypt hypertrophy 




2.2 THE PATHOGENESIS OF CD 
CD occurs in genetically predisposed people bearing the human leukocyte antigen HLA 
DQ2/DQ8. However, the presence of HLA-DQ8 is necessary but not sufficient for the CD 
pathogenesis. Other genetic risk factors, involved in the barrier and immune functions, also 
contribute to disease susceptibility although accounting for a small portion of the overall risk 
(Bouziat et al., 2017; Sciurti et al., 2018). 
Gluten is made up of gliadins and glutenins, both of which are capable of triggering CD, with 
gliadins causing an immediate and transient increase in intercellular TJ permeability of 
intestinal epithelial cells (Drago et al., 2006). Several properties of gluten may explain their 
toxicity in patients with CD. Indeed, gluten proteins have a high concentration of proline and 
glutamine residues, which renders them resistant to enzymatic degradation by digestive 
enzymes, leaving large, potentially immunogenic peptides that may reach the underlying 
mucosa (Chander et al., 2018). One of these peptides is known as p31-43, or 33-mer, and 
is highly immunogenic in CD patients. When in the intestinal lumen, gliadin binds the 
chemokine CXC motif receptor 3 (CXCR3), promoting the activation of MYD88 thus inducing 
the release of zonulin in the lumen. The latter protein binds the EGFR and PAR2, which 
complex ignite the signaling pathway leading to zonula occludens protein phosphorylation, 
responsible for tight junction disassembly (figure 7). When gluten peptides cross the 
epithelial barrier, the high proline and glutamine content renders them a very good 
substrates for tissue transglutaminase (TG-2) (Vader et al., 2002), which plays a key role in 
CD pathogenesis. This is a member of the transglutaminase family characterized by several 
enzymatic activities (Ca2+-dependent transamidating activity, GTPase/ATPase, protein 
disulfide isomerase, protein kinase) as well as nonenzymatic functions based on its non-
covalent scaffold interactions with many cellular proteins (Odii & Coussons, 2014). Due to 
its multifunctionality, TG2 has been reported to have a complex biology playing a role in a 
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variety of cellular processes, such as differentiation, survival, apoptosis, autophagy, and cell 
adhesion (Tatsukawa et al., 2016). Once activated, TG2 deamidates gluten peptides, with 
this interaction being influenced by the initial imprinting of the innate immune system through 
the upregulation of IL-15, promoting the CD4+ T cell adaptive immune response (figure 7) 
(Tang et al., 2009). Thus, TG2 converts glutamines of the gluten peptides into negatively 
charged glutamic acid residues. These negatively charged residues, together with the 
presence of proline residues, increase the ability of peptides to bind the HLA-DQ2/8 on 
APCs (Bergseng et al., 2015; Molberg et al., 1998), which are than presented to gluten 
specific CD4+ T cells, inducing their prompt activation, migration to the small intestinal 
lamina propria, production/release of proinflammatory cytokines, such as IFNꝩ,  
metalloproteases, and keratinocyte growth factor by stromal cells, which induces cryptal 
hyperplasia and villous blunting, secondary to intestinal epithelial cells death induced by 
intraepithelial lymphocytes (IELs) (figure 7) (Pagliarini et al., 2015). Additionally, active CD 
is also characterized by membrane bound IL-15 overexpression on enterocytes, causing 
overexpression of the natural killer (NK) receptors CD94 and NKG2D by CD3+ IELs (Jabri 
& Abadie, 2015). Crypt hyperplasia has been hypothesized to be the consequence of an 
imbalance between continuous tissue damage, due to the mucosal autoimmune insult 
described above, and inability of the stem cells to compensate. The epithelial damage is 
mediated by cytotoxic intraepithelial lymphocytes which recognize ligands produced by 
inflammatory stimuli on the surface of the intestinal epithelium (Green & Jabri, 2003). 
Indeed, gliadin peptide 33-mer (p31–43) is responsible for the activation of innate immunity 
of the intestinal epithelial cells (Maiuri et al., 2003). Thus, the gliadin peptides can also 
directly stimulate the immune response of macrophages and dendritic cells through pattern 
recognition receptors (PRR), such as toll-like receptors (TLRs) 4 (Visser et al., 2009), which 
leads to the maturation of these cells and the secretion of pro-inflammatory cytokines (e.g., 
IL-1b, IL-8, TNFa and MCP-1). Consequently, the adaptive immune response directed 
19 
 
against gluten is enhanced, and the intestinal permeability is increased (Schuppar et al 
2009). 
 
Figure 7. CD pathogenesis. gliadin peptide (p31-43 or 33mer) interacts with CXCR3 on 
the apical side of epithelium (1) inducing a myeloid differentiation primary response 88-
dependent release of zonulin (2). Zonulin interacts with the intestinal epithelium and triggers 
increased intestinal permeability (3). Functional loss of the gut barrier facilitates gliadin 
peptide translocation from lumen to the lamina propria (4). Gliadin peptides allow the release 
of IL-15, keratinocyte growth factor, and IL-8 (5), with consequent recruitment of neutrophils 
in the lamina propria (6). Contemporaneity, alpha-amylase/trypsin inhibitors engage the Toll 
like receptor 4–MD2–CD14 complex with subsequent upregulation of maturation markers 
and release of proinflammatory cytokines (7). Then there are the innate immune-mediated 
apoptosis of intestinal cells with subsequent release of intracellular tissue transglutaminase, 
gliadin peptides are partially deamidated (8). Deamidated gliadin is recognized by DQ2/8+ 
antigen presenting cells (9) and then presented to T helper cells (10). T helper cells guide 
the activation and maturation of B cells, producing IgM, IgG, and IgA antibodies against 
tissue transglutaminase (11). T helper cells also produce IFNγ and TNFα  (12), which in turn 
further increase gut permeability and, together with T killer cells, initiate the enteropathy. 
Damaged enterocytes express CD71 transporter also on their apical side, resulting in retro-
transcytosis of secretory IgA-gliadin complexes (13), thus potentiating gluten trafficking from 
gut lumen to lamina propria. At the end the interaction between CD4+ T cells in the lamina 
20 
 
propria with gliadin induces their activation and proliferation, with production of 
proinflammatory cytokines, metalloproteases, and keratinocyte growth factor by stromal 
cells, which induces crypt hyperplasia and villous blunting secondary to intestinal epithelial 
cell death induced by intraepithelial lymphocytes. The hyperplastic crypts (14) are 
characterized by an expansion of the immature progenitor cells compartment (WNT) and 
downregulation of the Hedgehog signaling cascade. An increased number of stromal cells 
known to be part of the intestinal stem cell niche and increased levels of bone morphogenetic 
protein antagonists, like Gremlin-1 and Gremlin-2, may further contribute to the crypt 
hyperplasia present in celiac disease. 
 
3. THE GUT MICROBIOTA  
In the last decade, epidemiological, physiological and omics-based studies, in addition to 
cellular and in vivo studies, indicated that a considerable part of the environmental influence 
on human health and disease risk may be mediated or modified by microbial communities 
in our body (Marchesi et al., 2016). These communities, named microbiota, include a large 
number of interacting bacteria, bacteriophages, archaea, eukaryotic virus and fungi that live 
together on human surfaces and in all body cavities. Most of them are commensal or 
mutualistic microorganisms. The whole intestinal microbial genes (the microbiome) in an 
individual represents a genetic repertoire that is more than one order of magnitude higher in 
genes than the human genome (Marchesi et al., 2016). 
Recent evidence indicates that intestinal microbiota plays a crucial role in maintaining the 
homeostasis of the human body. This studies suggest that microbiota may contribute to the 
pathogenesis of several metabolic disease such as obesity, type 2 diabetes, non-alcoholic 
liver disease, cardio-metabolic diseases and malnutrition (Marchesi et al., 2016). It is 
important to note that most microorganisms inhabiting humans reside in the intestine, and 
the gut microbiota composition is influenced by the mode of birth, lifestyle, infant feeding, 
and medication of the human host. The gut microbiota plays an important role in the training 
of immunity, digesting food, modifying drug action and metabolism, regulating gut endocrine 
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function and neurological signalling, eliminating toxins, and producing numerous 
compounds that influence the host (Lynch & Pedersen, 2016). For example, there are 
indications for a role of the gut microbiota in mediating some of the environmental effects in 
obesity pathogenesis. This evidence indicated that there is a transferable obesity-
associated microbiota that can induce weight gain in lean mice (Turnbaugh et al., 2006). 
Subsequent studies have also shown differences in the gut microbiota of individuals with 
obesity and lean individuals (Turnbaugh et al., 2006). 
The microbiota integrity and its dynamic interactions with the body are essential for 
maintaining a healthy state and homeostasis while its alterations may contribute to the 
development of diseases. Indeed, it has been hypothesized that alterations in the gut 
microbiota play a pathogenic role in celiac disease (Collado et al., 2007), and recent studies 
suggest that a dysbiosis of the gut microbiota leads to the activation of innate immunity in 
patients with CD (Szebeni et al., 2008). 
Bacterial products on the gut surface are detected by specific receptors for the pathogen-
associated molecular pattern (PAMP) called TLRs. Each of these receptors is able to 
recognize a specific bacterial product which can lead to the activation of various signaling 
pathway in the cell (Round & Mazmanian, 2009). The innate immune reaction is immediate 
and is usually directed toward microbial antigens which bind the toll-like receptors. In CD 
patients this reaction is directed toward gluten (Garrett et al., 2010; Meresse et al., 2012). A 
recent study demonstrated an increased expression of TLR4 and TLR2 in both inflammatory 
bowel diseases (IBD) and CD, suggesting a role of dysbiosis in the initiation of intestinal 
barrier damage (Szebeni et al., 2008).  
The relationship between the gut and its microbial content allows the identification of 
dangerous and harmless bacteria as well as food antigens (Nagler-Anderson, 2001). In 
addition, the microbiota contributes to maintaining both the intestinal barrier function, by 
increasing the proliferation of epithelial cells, and the integrity of the intestinal epithelium 
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through the translocation of proteins forming TJs and stimulating the expression of genes 
involved in the maintenance of desmosomes (Kim et al., 2010). As a result, it also regulates 
the development of the vascular architecture of the villi (Stappenbeck et al., 2002). 
 
 3.1 CD TREATMENT 
Actually, the only treatment for celiac disease is life-long gluten-free diet (GDF).  
Early diagnosis of celiac disease is very important to prevent some complication that could 
be irreversible, such as growth retardation, osteoporosis and abnormal dentition (Freeman 
et al., 2011)). Many studies suggest that delaying and gradually introducing gluten in the 
diet can reduce the risk of celiac disease development in the childhood (Parzanese et al., 
2017)  
3.2 CD AND PROBIOTICS 
GFD represents a very hard problem for many patients because traces of gluten are found 
in the most of processed foods, and a strict gluten-free diet inevitably limits the social 
activities of patients. Furthermore, GFD may be rich in high glycemic index foods which can 
increase insulin resistance and the risk of obesity and cardiovascular diseases. In the last 
decade, many new therapies have been suggested to improve GFD or to replace it. The 
microbiota and the related dysbiosis in CD patients have shifted the focus of new therapies 
for CD regarding the use of probiotics. Indeed, recent studies suggest that probiotics and 
prebiotics administration could be useful in the treatment of celiac disease patients (de 
Sousa Moraes et al., 2014). Probiotics administration could modulate the composition and 
functions of the intestinal microbiota, both to defer or to avoid the onset of CD, and could 
also be useful following a GFD when the normal microbial composition has not been 
completely restored. Benefits could come from the regulation of the immune response, the 
degradation of toxin receptors, the competition for nutrients, and the production of inhibitory 




4. CYSTIC FIBROSIS AND CD 
Several lines of evidence led to the hypothesis of a link existing between the two human 
disorders such as CD and Cystic fibrosis. 
 
4.1 CYSTIC FIBROSIS 
Cystic fibrosis (CF) is a human disease caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein. CF is the most common rare 
disease in the Caucasian population (Cutting, 2015), mainly affecting the lung, but also gut, 
kidneys, pancreas, and liver (Quittner & Li-Rosi, 2020). Mutated CFTR causes salt water 
balance dysfunction, resulting in dehydration of the secretions (thick mucus) and excessive 
loss of salt in sweat. Unfortunately, there is not yet a cure for CF (Massie & Delatycki, 2013). 
A defective CFTR causes an increase of reactive oxygen species (ROS), early activation of 
TG2, epithelial stress, autophagy inhibition (Ferrari et al., 2017; Luciani et al., 2010) and, 
TG2-mediated increased nuclear translocation of NF-κB, resulting in enhanced levels of pro-
inflammatory cytokines (Luciani 2010). 
CFTR is a membrane protein belonging to the ABC transporter family functioning as a 
chloride/anion channel in epithelial cells. It is composed by two nucleotide-binding domains 




Figure 8. Structure of CFTR protein. CFTR is composed of two transmembrane domains, 
two nucleotide binding domains (NBD1 and NBD2) and a regulatory domain (R). CFTR 
chloride channel can be activated through phosphorylation of the R domain and by ATP 
binding to and hydrolysis by NBDs. 
 
There are over 1500 different mutations associated to cystic fibrosis 
(http://www.genet.sickkids.on.ca). Most mutations identified in CF patients occur in the first 
nucleotide binding domain (NBD1), while very few occur in the NBD2, of CTFR protein.  The 
deletion of phenylalanine at position 508 (F508del) is the most common mutation in CF 
(Quittner & Li-Rosi, 2020).  Homozygous F508del (CFTR-ΔF508) is related to defective 
intracellular processing and trafficking (Ward & Kopito, 1994) and results in a loss of function 
mutation. Importantly, the mutated protein is retained in the endoplasmic reticulum (ER) and 
rapidly degraded. As a result, CFTR-ΔF508 fails to reach the apical membrane(Cheng et 




4.2 CF AND CD CO-MORBIDITY 
The co-morbidity CF and CD were reported since 1960s in a large cohort of patient (Fluge 
et al., 2009). There are 4% prevalence of positive serological marker of CD (Fig.9). The NF-
κB activation in CF leads to increased levels of pro-inflammatory cytokines, such as IL-17A, 
IL-21 and IL-15, involved in the intestinal homeostasis. These concerns led to the  
hypothesis that CFTR is potentially involved in the pathogenesis of CD. 
 
Figure 9. Prevalence of CD in Paediatric group of 288 patients with CF at the Paediatric 
Cystic Fibrosis Care Unit of the University of Naples Federico II during the last 10 years. 
Patients                             N° Percentage 
Cystic Fibrosis  288  
CF patients with: 










a. Data from children with Cystic Fibrosis who have received diagnosis of Celiac Disease 
 
b.  Data from children with Cystic Fibrosis who have shown fluctuant serological anti-tissue 
anti-transglutaminase and anti-endomysial antibodies above the cut-off level at least once.  
N.A. Not available; CF Cystic Fibrosis; tTG  anti‐tissue transglutaminase; EMA anti‐endomysial antibodies ̂ , 
Marsh classification of intestinal lesion; *, highest antibody titer above the cut‐off level registered at leat 








P1 F508del/F508del 104 76.1 + T3b DQ8 
P2 2789+5G>A/Y849X 106 21.4 + T3c N.A. 
P3 G542X/2184insA 94 17.9 + T3a DQ2 
P4 F505del/D1152H 44 >200 + T3c DQA1*03 
P5 F508del/L732X1 80 >200 + T3c DQ2 
P6 171711G>A/D579G 67 23.3 + T3b DQ2 
P7 D1152H/D579G 15 >200 + T3c DQ2 












P9 N1303K/G1244E 98 + + N.A DQ2 
P10 F508del/G542X 109 + + T0 DQ2 
P11 F508del/F508del 85 + + N.A DQA1*05 
































The aims of my PhD project were: 
 
 to characterize in vivo pre-clinical mice models of celiac disease. In vivo models can 
represent an advantageous tool to study CD pathogenesis and to define new 
therapeutic strategies  
 
 to decipher the molecular mechanisms underlying the onset and development of this 
disorder. Particularly, to unveil the hypothetical link between CF and CD. To this 
aim, I focused on CFTR protein function in vivo under gliadin stimulation, to induce 
CD 
 
 finally, due to the key role played by the microbiota and its dysbiosis in several 
inflammatory diseases such as IBD and CD, I evaluated the impact of probiotics 






































MATERIALS AND METHOD 
6.1 Mice and treatments 
 BALB/c mice (background BALB/cAnNCrl; Papista et al, 2012) were purchased from 
Charles River (Calco(LC), Italy). Three-generation gluten-free diet (Mucedola srl, 
Milan), male and female, were challenged with gliadin for 4 weeks (Papista et al., 
2012; Villella et al., 2019). Mice were challenged via gavage for 4 weeks with (i) 
vehicle alone or (ii) gliadin (SigmaAldrich); 5 mg/daily for 1 week and then 5 mg/daily 
thrice a week for 3 weeks; (Galipeau et al, 2011; Papista et al, 2012; Larsen et al, 
2015; Moon et al, 2016). At the end of the fourth week, mice were challenged every 
day via gavage for two weeks with gliadin in presence or absence of Probiotic 1 
(5,7x105±2.0X105/day) or Probiotic 2 (P2: 8,5x105±2.0X105/day /day) formulations. 
(n = 6 mice per group of treatment). All described mice, male and female were 8 
weeks old.  
 
 Prediabetic NOD (Non-obese diabetic) mice were purchased from Charles River 
(Calco (LC), Italy) . Diabetes incidence was followed weekly measuring blood glucose 
levels with a Contour glucose meter (Bayer; US). At time of 12–13 weeks, female 
mice with manifested diabetes (> 250 mg/dl) were challenged as described in (i) or 
(ii). 
 
 NOD.scid AB0nullDQ8 mice (NOD DQ8tg, transgenic mice expressing HLA-DQ8 in 
an endogenous MHC class II-deficient background were backcrossed to NOD mice 
for 10 generations and intercrossed to produce congenic NOD AB0 DQ8 mice 
(Galipeau et al., 2011). NOD-DQ8 mice, were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA) and were weaned and maintained on a low-fat 
(4.4%), gluten-free diet (Mucedola srl, Milan), and bred in a conventional, specific 
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pathogen-free colony at the San Raffaele Scientific Institute SOPF animal house 
(Milan, Italy). Mice were challenged as described in (i) or (ii). 
 
 CF mice homozygous for the F508del-CFTR in the FVB/129 outbred background 
(Cftrtm1EUR, F508del, FVB/129, abbreviated CF) and Wild Type littermates were 
obtained from Bob Scholte, Erasmus Medical Center Rotterdam, The Netherlands. 
Transgenic KO Cftr mice (B6.129P2-KOCftrtm1UNC, abbreviated CftrKO), and Wild 
Type littermates, were purchased from The Jackson Laboratory (Bar Harbor, ME, 
USA). Mice were treated as previously described in (i) or (ii) (Villella et al., 2019).  
 
 Balb/c mice were obtained from Charles River (Calco). 8 weeks old of three-
generation gluten free mice (Mucedola), for a total of 36 mice, were randomly divided 
into 6 groups (G1÷G6), composed of 6 mice/group. The G1 was challenged with a 
gluten free diet for all along with the time of the experiment; the G2÷G4 were 
challenged via gavage with gliadin (Sigma; 5mg/daily for 1 week, then 5 mg/daily 
thrice a week for 3 weeks) for 4 weeks (Villella et al, 2019; Papista et al, 2012). At 
the end of the fourth week, mice from G2÷6 were challenged with gliadin alone (G2) 
or in combination with Probiotic 1 (P1; G3) or Probiotic 2 (P2; G4), or with P1 (G5) or 
P2 (G6) alone, every day via gavage, for another two weeks (P1 2mld/day; P2 




Figure 10. Schematic representation of the experimental procedure 
At the end of every last daily treatment, mice were anesthetized with avertin 
(tribromoethanol, 250 mg/kg, Sigma-Aldrich, T48402) and euthanized; the intestines were 
collected.  
These studies and procedures were approved by the local Ethics Committee for Animal 
Welfare (IACUC No 583, 849) and conformed to the European Community regulations for 
animal use in research (2010/63 UE). 
 
6.2 Ussing chamber 
Chambers for mounting either transwell cell cultures or mouse tissue biopsies were obtained 
from Physiologic Instruments (model P2300, San Diego, CA, USA). Chamber solution was 
buffered by bubbling with identical Ringer solution on both sides and were maintained at 
37°C, vigorously stirred, and gassed with 95% O2/5% CO2. Cells or tissues were short 
circuited using Ag/AgCl agar electrodes. A basolateral-to-apical chloride gradient was 
established by replacing NaCl with Na-gluconate in the apical (luminal) compartment to 
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create a driving force for CFTR-dependent Cl secretion (figure 11). To measure stimulated 
Isc, the changed sodium gluconate solution, after stabilization, was supplied with 100 mM 
amiloride. Agonists (forskolin) were added to the bathing solutions as indicated (for a 
minimum of 5 min of observation under each condition) to activate CFTR channels present 
at the apical surface of the epithelium (either cell surface or lumen side of the tissue), and 
CFTRInh-172 (10 mM) was added to the mucosal bathing solution to block CFTR-dependent 
Isc. Short-circuit current [expressed as Isc (lA/cm2)] and resistance were acquired or 
calculated using the VCC-600 transepithelial clamp from Physiologic Instruments and the 
Acquire&Analyze23 software for data acquisition (Physiologic Instruments), as previously 
described (Gondzik & Awayda, 2011; Marchelletta et al, 2013; Tosco et al, 2016; Romani et 
al, 2017;Villella et al., 2019). 
 
Figure 11: schematic representation of Ussing Chamber  
 
6.3 Permeability assay 
The FITC-D4000 test in treated BALB/c mice (as described in mice and treatments section) 
was performed as previously described (Volynets et al., 2016). Briefly, FITC-D4000 (Sigma-
Aldrich) was administered to mice by oral gavage at a concentration of 600 mg/kg body 
weight and a volume of 200–300 ml, using a stock solution of 50 mg/ml. After gavage, the 
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mice remained in the metabolic cages until the experiments were completed and the mice 
were euthanized. One hour after gavage, the animals were anesthetized and blood was 
taken by cardiocentesis, heparinized, and then centrifuged (10 min, 12,000 g,4 °C). Plasma 
was light protected and stored at -80°C for photometric analysis of FITC-D4000. Each 
plasma was diluted in an equal volume of phosphate buffered saline (PBS, pH 7.4). 
Standards (range 50–0.312 µg/ml) were obtained by diluting the FITC-D4000 gavage stock 
solution in PBS. An amount of 100 µl of both diluted animal samples and standards, as well 
as blanks (PBS and diluted plasma from untreated animals), were transferred into black 96-
well microplates. Analysis of the FITC-D4000 concentration was carried out with a 
fluorescence spectrophotometer (Multi-Detection Microplate Reader) at an excitation 
wavelength of 485 nm and an emission wavelength of 528 nm. The same analysis was 
previously described in (Villella et al., 2019). 
 
6.4 Real-Time and reverse transcription analysis 
Trizol reagent (Invitrogen) was used to extract total RNA. The AMV Reverse Transcriptase 
kit (Promega; Madison, WI, US) was used to produce cDNA following the manufacturer’s 
recommendations. Quantitative PCR reactions were performed by using C1000Touch 
CFX96 Biorad thermocycler. The Maxima SYBR Green/ROX qPCR Master Mix (Thermo 
Scientific) was used to produce fluorescently labeled PCR products during repetitive cycling 
of the amplification reaction and the melting curve protocol was used to check for probe 
specificity. Primer sets for all amplicons were designed using the IDT PrimerQuest Tool 
(https://eu.idtdna.com/Primerquest/Home/Index).The sequences of mouse primers were as 
follow: 
















The result of the fluorescent PCR was expressed as the threshold cycle (CT). The CT is 
the difference between the CT for the specific mRNA and the CT for the reference mRNA, 
GAPDH. To determine relative mRNA levels, 2 was raised to the power of CT (the 
difference between the CT from treated cells and the CT from untreated cells). 
 
6.5 Immunoblot 
The whole small intestine lysates were obtained by using the Cell Lytic buffer (Sigma) 
supplemented with a protease inhibitors cocktail (Sigma) plus phosphatases inhibitors 
(Na3VO4 1 mM; NaF 10 mM), and resolved by electrophoresis through SDS-PAGE, and 
electroblotted onto nitrocellulose (Protran, Sigma) membranes. Membranes were incubated 
with indicated primary antibodies in 5% non-fat dry milk (Bio-Rad) in PBS plus 0.1% 
Tween20 overnight at 4°C. Primary antibodies were: anti-CFTR (clone M3A7 Abcam 
ab4067) 1:500, anti-TG2 (NeoMarkers) 1:750, and anti-Actin (Cell Signaling) 1:2000. 
35 
 
Detection was achieved using horseradish peroxidase-conjugate secondary antibody 
(1:5000; Jackson ImmunoResearch; Cambridge, UK) and visualized with ECL plus 
(Amersham Biosciences; Amersham). Images were acquired by using a ChemiDoc™ Touch 




ELISA was performed on tissue samples using standard ELISA kits (R&D Systems) for IL-
15, IL-17A, IFN-γ. According to the manufacturer’s instructions, samples were read in 
triplicate at 450 nm in a microplate Reader (Bio-Rad, Milan, Italy) using Microplate Manager 
5.2.1 software. Values were normalized to protein concentration evaluated by Bradford 
analysis. 
 
6.7 H/E staining 
After surgical removal of the small intestine, samples were fixed in formalin at room 
temperature, dehydrated and embedded in paraffin. 8m thick sections were collected by 
using a microtome (Leica). All sections were mounted on slides, stained with haematoxylin 
and eosin (Bio Optica) and images were acquired by using a Nikon Eclipse Ci Microscope, 
a Plan APO 10X Objective, and the NIS-Elements Software (Nikon). 
 
6.8 Probiotics formulations 
Probiotics were supplied by PROBIOTICAL SpA, in lyophilized powder. The P1 formulation 
contains two strains of Bifidobacterium breve, the B632 (DSM 24706) and BR03 
(DSM16604) at 2x109 live cells (AFU)/g, while the P2 formulation contains the Lactobacillus 
plantarum LP14 (DSM 33401), L. casei subsp. paracasei LPC09 (DSM 24243) and the 
Lactobacillus rhamnosus LR04 (DSM 16605) at 3x109 live cells(AFU)/g. The study materials 
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were analyzed by Probiotical Research srl, Novara, Italy, via flow cytometry (ISO 
19344:2015 IDF 232:2015) to confirm target cell count. P1 or P2 were resuspended in PBS 
and administrated as described. 
 
6.9 Statistical analysis 
All experiments were performed at least in triplicate and statistical analysis was performed 
using GraphPad Prism 6. The Student’s t test and ANOVA was used to determine statistical 
















































7.1. IN VIVO MODELS OF GLUTEN SENSITIVITY 
The identification and development of in vivo pre-clinical models of celiac disease can 
represent a useful tool to study disease pathogenesis and to define new therapeutic 
strategies. Such in vivo models could allow to decipher the molecular mechanisms through 
which prior activation of the innate response can pave the way for T cell response upon 
gliadin exposure, and potentially unravel the contribution of the intestinal microbiota to the 
pathogenic cascade leading to celiac disease.   
To this aim, I screened the literature to identify appropriate animal models sensitive to 
gluten.  
Therefore, I selected 3 mouse models of CD: 
 Balb/c mice inbred for at least three generation and fed with a gluten-free diet. 
Gluten sensitivity was induced by feeding mice with food containing gluten for 30 
days (Papista et al., 2012), model 1; 
 NOD mice fed either with a gluten-free or standard diet (Larsen et al 2015), model 2; 
 Gluten sensitive human leukocyte antigen (HLA) DQ8 transgenic mice (Galipeau et 
al., 2011), model 3. 
Then, I tested the response of these mice models to gluten exposure according to literature 
(Moon et all 2016; Papista et al 2012; Galipeau et al., 2011). To this aim, gluten sensitivity 
was induced in Balb/c mice by feeding them with a gluten free diet (commercial food pellets) 
for three generation (model 1). Mice were then challenged with gliadin for 4 weeks, while 
mice fed with a gluten-free diet were used as matched controls.  
NOD mice (model 2) naturally develop diabetes (females) at about 12 weeks of age. 




NOD DQ8 mice (model 3) maintained on a low-fat (4.4%) gluten-free diet, were also 
challenge with or without gliadin for 4 weeks.  
 
7.2 Gliadin increases intestinal permeability, TG2 levels, and cause villous atrophy in 
vivo 
Under physiological conditions, access of gliadin to gut associated lymphoid tissue is 
prevented by competent intercellular tight junctions (TJs), thus limiting the passage of 
macromolecules through the intestinal epithelial barrier. However, in predisposed 
individuals, gliadin exposure leads to TJ disassembly, thus increasing intestinal permeability 
and chronic inflammation. To test this hypothesis, I evaluated the permeability of intestinal 
barrier in gluten-free mice exposed to gliadin (model 1), as described in the previous section, 
by using FITC-conjugated Dextran. To this aim, gluten sensitive mice (GSM) fed for at least 
three generation with a gluten-free diet) were gavaged with gliadin for 4 weeks. At the last 
day of treatment, mice were orally gavaged with a single dose of FITC-Dextran for 4h 
(44mg/100g body weight), mice were sacrificed and blood was than collected. Fluorescence 
of isolated plasma was measured and used to evaluate the permeability of the intestinal 
barrier. Data reported in figure 12A clearly show an increased intestinal permeability of mice 
challenged with gliadin, compared to matched controls.  
TG2 is also a very important actor in CD, deamidating gliadin peptides, thus increasing their 
binding affinity to the disease-predisposing human leukocyte antigen (HLA) DQ2 and DQ8 
molecules, and enabling a strong immune response to be launched. To confirm the 
involvement of TG2, a western blotting analysis was performed on lysates from the small 
intestine of GSM exposed to gliadin. Data reported in figure 12B show an enhanced 
expression of TG2 in mice challenged with gliadin compared to controls.  
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The CD-associated immune response leading to chronic intestinal inflammation determines 
shortening of the villi lining the small intestine, resulting in villous atrophy. This condition was 
also evident in the mouse model 1 exposed to gliadin, as shown in figure 13.  
Figure 12. Intestinal permeability and TG2 expression in Balb/c mice  challenged with 
gliadin. GSM were challanged with gliadin and intestinal permeability was evaluated by 
monitoring the release of FITC-Dextran in the plasma (A). Plasma concentration of FITC-
Dextran was measured 4h after gavage. n=3 mice per group of treatment.  T-test** p<0.05. 
B) The expression levels of  TG2 was evaluated in intesinal cell lysates from gliadin exposed 
and matched control mice, by western blotting analysis. Images are representative of 
experiments performed in triplicete. Actin was used as loading control. 
 
Figure 13. H/E staining of small intestine. GSM were exposed or unexposed to gliadin for 




The same treatment were done in mice gliadin non-sensitive. In this mice there is no 
evidence of CD development (data not show). 
 
7.3 Activation of adaptative and innate response in vivo 
CD is a T-cell mediated disease, in which gliadin derived peptides activate lamina propria 
infiltrating T lymphocytes which release proinflammatory cytokines. IL-15, exerts many 
biological functions essential for the maintenance and function of multiple cell types. The 
dysregulated expression of IL-15 contributes to breaking oral tolerance to gluten and lead 
to CD pathology. The expression/release of this pro-inflammatory cytokine was than 
evaluated in small intestine lysates from GSM exposed to gliadin, model 1, compared to 
matched controls challenged. Figure 14A (left panel) shows a clear increase of IL-15 gene 
expression compared to control, measured as mRNA levels. Moreover, the 
production/release of the cytokine is also confirmed by the enhanced protein level evaluated 
by ELISA, in small intestine lysates of gliadin challenged mice compared to controls 
(Fig.14B, left panel). 
In parallel, the expression of two other proinflammatory cytokines, IL-17A and IFNꝩ, was 




Figure 14. The gluten sensitive Balb/c mouse model. GSM were challenged with or 
without gliadin for 4 weeks, and the expression of IL-15, IL-17A or INFᵧ was evaluated at 
both mRNA (A) and protein (B) level, in homogenate small intestines, by qRT-PCR and 
ELISA, respectively. T-test ***P<0.001. 
 
IL-17A mainly promotes the generation of other pro-inflammatory cytokines and 
chemokines, which leads to the attraction of neutrophils and macrophages to 
the inflammation site, while IFNꝩ represents the primary effector of epithelial permeability 
in CD. As reported in figure 13, both cytokines were efficiently upregulated at both mRNA 
(Fig.14A, middle and right panels, respectively) and protein (Fig.14B, middle and right 
panels, respectively) levels. Collectively these data indicate a proinflammatory condition in 
small intestine of GSM exposed to gliadin, compared to matched controls.  
Then I evaluated the production of the same pro-inflammatory cytokines also in the second 
model of gluten sensitivity mice, the non-obese diabetic (NOD) female mice (model 2). To 
this aim, the spontaneous development of autoimmune type-1 diabetes was evaluated by 
measuring the blood glucose levels (weekly) within 12 weeks. Next, upon diabetes induction, 
mice were orally administered with gliadin, and the levels of IL-15, IL17A or IFNꝩ were 
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evaluated at both mRNA and protein levels, by qRT-PCR and ELISA, respectively, and 
compared to matched controls. 
Figure 15. The NOD mice model. Upon diabetes induction, animals were challenged with 
or without gliadin for 4 weeks, and the production of IL-15, IL-17A and INFᵧ was evaluated 
at both mRNA (A) and protein (B) levels, by qRT-PCR or ELISA, respectively, in homogenate 
small intestines. t test ***P<0.001, **P<0.05. 
 
Data shown in Figure 15 clearly confirm an enhanced production of the pro-inflammatory 
cytokines stimulated by gliadin exposure, compared to controls, also in this in vivo model. 
Finally, the same analysis was also performed by using the selected in vivo model 3. To this 
aim, NOD mice expressing the CD-predisposing HLA molecule DQ8 (NOD-DQ8) were 
treated or untreated with gliadin for 4 weeks, and the expression of IL-15 and IFNg were 
evaluated by ELISA. Data reported in figure 16 indicate an enhanced gliadin-dependent 







Figure 16. The NOD DQ8 mouse model. Mice were challenged with or without gliadin for 
4 weeks, and IL-15 and INFᵧ protein levels were evaluated in the small intestine tissue 
homogenate by ELISA. T-test ***P<0.001 
The same treatment were done in mice non-sensitive. In this mice there is no evidence of 
CD development (data not show). 
 
8. THE GLIADIN-CFTR CONNECTION 
An increased prevalence of diagnosed CD has been reported in patients affected by cystic 
fibrosis (CF; 4% prevalence of positive serological marker for CD (Fluge et al., 2009)), 
suggesting a potential link between the two diseases. CF is associated with improper 
function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a 
transmembrane ion channel. It is caused by mutations of the cftr gene, a cyclic adenosine 
monophosphate (cAMP)-regulated anion channel, mediating chloride/bicarbonate transport 
across epithelia. CF usually leads to respiratory problems although intestinal problems are 
also observed in some of these patients, mainly because CFTR is highly expressed also 
along the epithelial of the gut. It is important to note that CFTR is not only a protein channel 
but is also a hub protein that directs a protein homeostasis network of epithelial cells. 
Therefore, this protein could conceivably represent the link between CF and CD, with gliadin 
potentially affecting the activity of CFTR at the small intestine intestinal surface. To test this 




8.1 Gliadin inhibits CFRT function in vivo, in the small intestine of gliadin sensitive 
mice 
To determinate if gliadin might impact on CFTR activity in the small intestine in vivo, mice of 
the three models described above were exposed or unexposed (controls) to gliadin for 4 
weeks, and the activity of CFTR was evaluated by using an ‘Ussing Chamber’ (UC). The 
small intestines of mice were mounted to the chamber, and a basolateral-to-apical chloride 
gradient was established. To measure the stimulated, short-circuit current (Isc), the sodium 
gluconate solution, after stabilization, was supplied with 100 mM amiloride. Agonists 
(forskolin) were added to the bathing solutions as indicated (for a minimum of 5 min of 
observation under each condition) to activate CFTR channels present at the apical surface 
of the epithelium (either cell surface or lumen side of the tissue), and CFTRInh-172 (10 mM) 
was added to the mucosal bathing solution to block CFTR-dependent Isc. Short-circuit 
current [expressed as Isc (lA/cm2)] and resistance were acquired. 
GSM Balb/c, model 1, NOD mice (upon diabetes onset), model 2, or NOD DQ8 mice, model 
3, challenged with gliadin for 4 weeks, showed a consistent and reproducible gliadin-
dependent reduced CFTR activity (Fig 17). These results, confirmed in all mice models, 






Figure 17. CFTR activity. GSM (A), NOD (B) or NOD DQ8 (C) mice were orally challenge 
with vehicle or gliadin for 4 weeks, and CFRT activity was measured by a UC. 
Representative traces of CFTR-dependent Cl- secretion is reported in the upper panels, 
while channel activity quantification of the peak CFTR inhibitor 172 (CFTRinh172) sensitive 
Isc in tissue samples (n=3 independent experiment). Mean ± SD of sample assayed; 
**P<0.01, ***P<0.001 vs challenged with gliadin (student’s t-test). 
 
Next, I investigate if CFTR protein levels are modulated by gliadin challenge. To this aim, 
protein levels of CFTR were evaluated in GSM exposed or unexposed to gliadin for 4 
weeks, by western blotting analysis. As shown in figure 18, a tremendous down-regulation 
of protein expression is clearly observed in the intestine of mice challenged with gliadin, 
compared to matched controls. The downregulation is may be due in part of a degradation 





Figure 18. Impact of gliadin on CFTR expression levels. GSM were challenged with or 
without gliadin for four weeks, and CFTR expression levels were evaluated by western 
blotting analysis, in small intestine homogenate. βActin was used as loading control. Images 
are representative of experiments performed in triplicate. 
 
8.2 Defective CFTR favours gliadin responsiveness in vivo 
To understand which is the role of CFTR in the pathogenesis of CD and to determine if the 
constitutive activation of innate immunity in the intestine of CF patients may favor the 
inflammatory and immune response to gliadin, we moved on to CFTR-deficient mice models 
such as: the CFTR Knock-out mice (KO CFTR) and mice expressing the most common loss 
of function CFTR mutation F508del (CF).  
Firstly, basal expression of TG2 and the pro-inflammatory cytokine IL-5, IL-17A and IFNg 
were evaluated in homogenates from small intestine of CF mice and compared to matched 




Figure 19. TG2 and pro-inflammatory cytokines expression in CF and CFTR-KO mice. 
CF and KOCFTR mice: the small intestine were homogenate and: TG2 expression levels 
were evaluated by western blotting analysis (A); βActin was used as loading control; 
expression levels of both IL-17A and IFNꝩ were evaluated by ELISA (B); while expression 
levels of IL-15 were evaluated by both qRT-PCR and ELISA (C). t-test ***P<0.001.  
 
Interestingly, data reported in figure 8 clearly show enhanced TG2 protein expression 
(Fig.19A) paralleled by increased levels of both IL-17A and IL-15, but reduced INFg in CF 
mice compared to controls (Fig.18B & C, respectively). 
Enhanced IL-15 basal expression in both CFTR-deficient mice was somehow expected, 
since constitutive activation of TG2 (Fig. 19A), observed in CF mice, is known to induce NF-
kB activation through IK-Ba protein sequestering (Luciani et all 2009). A similar feature was 
also evidenced in KO-CFTR mice model, compared to controls (Fig. 19C). 
It has been previously reported that CF epithelial cell produce less INFᵧ in response to 
external trigger, compared to non-CF epithelial cell (Nichols & Chmiel, 2015). A similar result 
was also evidenced in small intestine from our CF mice model (figure 19B).  
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Next, mice CFTR-deficient models were exposed to gliadin (4 weeks), with the littermate 
controls (WT). Interestingly, while WT mice were insensitive to gliadin stimulation, as 
expected, F508del (CF) mice showed enhanced expression of IL-17A, IL-15 and IFNg, upon 
gliadin exposure (Fig.20). 
Figure 20. Pro-inflammatory cytokines expression in CF mice. CF mice were treated for 
four weeks with or without gliadin. IL-17A, INFg and IL-15 levels in small intestine 
homogenate were evaluated by ELISA. T-test ***P<0.001, **P< 0.01. 
 
Collectively, these results indicate that the constitutive stress response and innate immunity 
activation in CFTR-deficient intestine might favour an immune response to gliadin.  
 
9. PROBIOTICS AND GLIADIN SENSITIVE MICE  
Currently, the only treatment for CD is lifelong adherence to a gluten-free diet (GFD). 
Because of the constraints of a gluten-free diet, alternative therapies are being developed, 
including agents that prevent gluten uptake from the mucosa, decrease immune activation, 
and reduced gluten exposure by either degrading or binding the molecule in the intestinal 
lumen (Tennyson et al., 2009).  
Millions of microorganisms live in our gastrointestinal tract and provide normal gut function. 
Dysbiosis is the imbalance of protective and pathogenic microbes in the host and has been 
associated with several human diseases, including CD. It’s still not clear whether dysbiosis 
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is one of the causes of CD or merely a consequence (Girbovan et al., 2017). In this context, 
probiotics, which are live microorganisms that confer a health benefit, may offer benefits to 
patients suffering from intestinal disorders such as irritable bowel syndrome and CD.  
Therefore, I tested two probiotic formulations in reducing the sensitivity to gliadin in the GSM 
model. 
 
9.1 Probiotics administration inhibits gliadin-mediated TG2 upregulation but does not 
restore CFTR physiological expression  
As described above, CFTR and TG2 are two key player in CD, since CFTR activity is 
inhibited by gluten derived peptides, resulting in protein destabilization and subsequent 
degradation. CFTR impairments also results in TG2 expression upregulation and activation 
which promotes the TG2-mediated gliadin peptides deamidation which, in turn, causes an 
increased binding affinity of deaminated peptides to the disease-predisposing human 
leukocyte antigen (HLA) DQ2 and DQ8 molecules, thus enabling a strong immune response 
contributing to the pathogenesis of celiac disease (Villella et al., 2019). 
Therefore, I evaluated both CFTR and TG2 mRNA and protein levels in the small intestine 
of Balb/c gluten sensitive mice (GSM) exposed to gliadin for four weeks and for two more 
weeks to gliadin in presence or absence of P1 or P2 probiotics formulations. Data reported 
in figure 20 show that gliadin exposure efficiently downregulated the expression of CFTR 
(A) and consistently elevated the expression of TG2 (B), at both mRNA and protein levels, 




Figure 21. Balb/c mice fed for at least three generation gluten free diet challenged 
with or without gliadin.  A) CFTR mRNA levels of small intestine homogenate of Balb/c 
mice fed with at least three generation gluten free diet treated with gliadin and P1 or P2 
(left). Immunoblot with anti CFTR antibody and anti βactin as loading control in whole lysate 
from small intestine homogenates of Balb/c mice fed with at least three generation gluten 
free diet treated with gliadin and P1 or P2 (right). B) TG2 mRNA levels of small intestine 
homogenate of Balb/c mice fed with at least three generation gluten free diet treated with 
gliadin and P1 or P2 (left). Immunoblot with anti TG2 antibody and anti βactin as loading 
control in whole lysate from small intestine homogenates of Balb/c mice fed with at least 
three generation gluten free diet treated with gliadin and P1 or P2 (right). Anova test P 
p<0.001 
 
upregulation, at both mRNA (Fig. 20B, right panel) and protein (Fig. 20B, left panel) levels, 
suggesting the ability of these probiotics formulations to potentially reduce the damaging 
effect exerted by gliadin peptides. However, our data also show that neither of the two 
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probiotic formulations were able to restore the physiological levels of CFTR, at both mRNA 
(Fig. 20A, left panel) or protein (Fig.20A, right panel) levels.  
Collectively, these data indicate that the bacteria of the two formulations do not prevent the 
formation of the active gliadin peptides generated by digestion, nor do they interfere directly 
(via cell-cell contact) or indirectly (via metabolites) with the binding of the latter molecules 
with the CFTR present in the cell membrane of intestinal epithelial cells, but nevertheless 
exert their beneficial activity downstream of this event, as confirmed by restored 
physiological TG2 expression.  
 
9.2 Dysregulated intestinal permeability due to gliadin exposure was restored by 
probiotics administration 
To support the previous hypothesis, we evaluated the effects of probiotics on intestinal 
permeability, compromised by glutes exposure. Therefore, I evaluated the intestinal 
permeability in vivo, in mice exposed 6 weeks to gliadin, by using FITC-Dextran 
administrated as a single dose (through gavage; 44mg/100g body weigth) 4h prior animal 
sacrifice (Papista et al., 2012; Villella et al., 2019). Fluorescence (FITC) measured in the 
plasma of mice and reported in figure 12A shows a considerable increased permeability in 
mice exposed to gliadin, compared to untreated control mice. These data are in line with the 
increased upregulation of both claudin 2 and 15 and downregulation of occludin (three TJ 
components), observed in mice exposed to gliadin compared to controls, and previously 
associated to impaired intestinal permeability (Garcia-Hernandez et al., 2017; Luettig et al., 
2015; Visser et al., 2009). Importantly, the co-administration of P1 or P2 consistently 
inhibited the intestinal permeability impairment mediated by the gliadin active peptides, as 
shown in figure 22A. Moreover, these results were also confirmed by the restored claudin 2 
and 15 physiological expression in mice exposed to gliadin in presence of P1 or P2 (Fig. 
22B upper right and bottom left panels, respectively). Noteworthy, although the co-
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administration of P2 almost completely restored the physiological expression of occludin, P1 
was not as efficient, potentially indicating a somewhat different mode of action of bacteria 
present in the two formulations (Fig. 22B, bottom left panel), although the P2 seems to exert 
a stronger impact in restoring the physiological permeability of the intestinal barrier, as 
indicated by data reported in Figure 22A (compare the two histograms on the right).  
 
Figure 22. Intestinal barrier permeability. A) FITC-Dextran plasma levels, marker of 
intestinal permeability in mice. Plasma concentration of FITC-Dextran 4000 measured 4h 
after gavage of a single dose to each mouse (44mg/100g body weigth). Quantification of 
plasma concentration from n=3 mice per group of treatment expressed as mean ±SD  ** 
p<0.05, *** p<0.001 (t-test). B) CLD2,CLD15 and OCLD mRNA levels of small intestine 
homogenate of Balb/c mice fed with at least three generation gluten free diet treated with 
gliadin and P1 or P2. ** p<0.05, *** p<0.001 (t-test) serum FITC Dextran. **p<0,01, p*** 






9.3 Gliadin-mediated small intestinal inflammation was completely buffered by 
probiotics 
Importantly, in line with data reported above, the presence of P1 or P2 also consistently 
inhibited the upregulation of the pro-inflammatory genes il-15, il-17a and ifn (Fig. 23). 
However, although both probiotics formulations completely inhibited the gliadin-mediate 
upregulation of IFN, a different effect was observed against the other two cytokines.  
 
Figure 23. Pro-inflammatory cytokines. INFᵞ, IL17 and IL15 mRNA levels of small 
intestine homogenate of Balb/c mice fed with at least three generation gluten free diet 
treated with gliadin and P1 or P2 ** p<0.05, *** p<0.001 (t-test). B) INFᵞ, IL17 and IL15 
protein levels from small intestine homogenates of Balb/c mice fed for at least three 
generation gluten free treated with gliadin for four weeks and P1 and P2.  ** p<0.05, *** 
p<0.001 (t-test). 
 
In particular, while P2 was more efficient (compared to P1) in inhibiting the gliadin-mediated 
IL-15 up-regulation, previously reported upregulate in CD and leading to an increase in 
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intraepithelial lymphocytes (Fig.23, right panel, compare the two rightmost conditions, P1 
and P2, p0,005)(Sollid, 2004), the P1 was the most efficient in reducing the gliadin-
mediated IL-17a up-regulation, which is involved in the pathogenic effect attributed to Th1 
cells in CD, compared to P2 (Fig.23, middle panel, compare the two rightmost conditions, 
P1 and P2, p0,05) (Lahdenperä et al., 2012).  
Collectively, our data indicate that probiotics administration consistently mitigates the toxic 
effects of the active gliadin peptides, although with a different extent, depending on the 
specific probiotic composition. 
 
9.4 ER stress was promptly induced by gliadin and efficiently inhibited by probiotics 
administration 
The endoplasmic reticulum (ER) is the site of synthesis and folding of lysosomal, membrane 
and secretory proteins, which, collectively, represent a large fraction of the total protein 
output of a mammalian cell. The homeostasis of this compartment and, therefore, its function 
is finely regulated by calcium concentration, redox potential and availability of chaperonins 
and co-chaperonins. Extracellular or intracellular insults compromising the homeostasis of 
this organelle results in an impaired function termed ER Stress consisting in a luminal 
accumulation of misfolded proteins which, in turn, activates the so-called Unfolded Protein 
Response (UPR) (Corazzari et al., 2017). The UPR function is primarily a pro-survival 
response aimed to restore the physiological functions of this compartment, through the 
activation of a finely regulated genetic program. However, acute of unsustainable stress will 
result in the activation of a UPR-mediated proapoptotic program (Lovat et al., 2008; 
Pagliarini et al., 2015)Therefore, due to the key role played by ER and UPR in cell functions 
and stress management, it is not surprising that ER Stress (and UPR) has been implicated 
in the pathogenesis of many diseases and in particular in inflammatory disease, potentially 
contributing substantially to disease onset and progression (Garg et al., 2012). In this 
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context, Caputo indicated the potential induction of ER Stress in vitro, in Caco-2 cells 
exposed to gliadin (Caputo et al., 2012). To validate this hypothesis, we evaluated the 
activation of UPR in our mouse model of CD, in animal exposed 6 weeks to gliadin, 
compared to unexposed controls. Data reported in figure 24 clearly show a consistent 
upregulation of the three main ER stress markers such as ATF4, ATF6 and XBP. 
Interestingly, ATF6 and XBP1 seem to be the most upregulated, compared to ATF4, and 
this is compatible with a chronic stress condition in which the UPR-related signalling 
pathways particularly involved in the degradation of misfolded proteins (ERAD) and gene 
expression regulation of chaperonins/co-chaperonins, regulated by XBP1 and ATF6, are 
highly active, compared to that particularly involved in the regulation of protein synthesis 
(PERK/eIF2a/ATF4 axis).  
Importantly, the exposure of gliadin-treated mice to P1 or P2 completely abrogated the 
gliadin-mediate upregulation of both ATF4 and XBP1s. Interestingly, while the expression 
of ATF6 was completely inhibited by both P1, in the same experimental conditions, P2 failed 
since the levels of this factor remained elevated (Fig.24, middle panel, compare the two 
rightmost conditions; p<0.01). Further studies are required to define the role of elevated 
ATF6 in presence of gliadin and P2.   
 
Figure 24. CD & UPR. ATF4, ATF6 and XBP1s mRNA levels of small intestine homogenate 
of Balb/c mice fed with at least three generation gluten free diet treated with gliadin and P1 
or P2 ** p<0.05, *** p<0.001 (ANOVA test). 
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Therefore, our data indicate that ER stress is involved in the pathogenesis of CD in vivo and 
that probiotics might be used to efficiently restore the homeostasis of this compartment, 













































Celiac disease is an autoimmune disorder occurring in genetically predisposed individuals 
bearing the human leukocyte antigen  (HLA) DQ2-DQ8, and primarily affecting the small 
intestine, caused by the ingestion of gluten, a protein contained in wheat and other grains. 
Symptoms include gastrointestinal problems like chronic diarrhoea, abdominal distention, 
malabsorption, loss of appetite, and among children failure to grow normally (Fasano, 2005). 
In the small intestine, gluten intake causes an inflammatory reaction leading to villous 
atrophy. Importantly, in genetically predisposed individuals, it has been reported a gluten-
dependent activation of TG2, leading to modification of gluten, resulting in the activation of 
CD4+T cells. Collectively, these mechanisms result in the production of proinflammatory 
cytokines responsible for the activation of intraepithelial CD8+T lymphocytes, which 
ultimately cause villus atrophy and disease pathology (Meresse et al., 2012). However, the 
exact molecular mechanisms through which gliadin can ignite a stress response, are still 
unclear. Therefore, the main objective of this study was to investigate the role of gliadin in 
the development of this enteropathy.  
To this aim, I established three in vivo mice models, consisting in: 
- Balb/c mice fed for at least three generation with a gluten free diet  
- NOD female mice (non-obese diabetic) that are prone to develop diabetes after 12 
weeks of age 
- NOD-DQ8 transgenic mice bearing human leucocyte antigen DQ8.  
CD pathogenesis was stimulated in all models by challenging mice with gliadin, for 4 weeks. 
Interestingly, we observed the production CD-related pro-inflammatory cytokines in all 
models, after gliadin challenge. Moreover, model 1 also shows villous lesion typical of CD, 
an enhanced expression of TG2, and an increased intestinal permeability.  
Altogether these results strongly indicate that the selected 3 mice models can efficiently and 
consistently recapitulate the human CD disorder. Therefore, they might be used to study the 
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molecular mechanisms underlying the onset of the pathology, together with the identification 
of new compounds and/or drug repositioning, to treat affected patients.  
Previous reports highlighted a potential link existing between CD and Cystic Fibrosis (CF), 
based on a prevalence of about 4% of CF patients characterized by anti-TG2-IgA 
autoantibodies, a serological marker of CD, positiveness. This observation was found even 
in the absence of villous atrophy, in several cohorts of patients affected by cystic fibrosis 
(Fluge et al., 2009). CF is a monogenic lethal disease worldwide (Cutting, 2015), caused by 
loss-of-function mutations of the gene coding for CFTR, a protein strongly expressed all 
along the intestine (Gadsby et al, 2006; Ooi & Durie, 2016). Then, to test whether CFTR 
might represent the molecular link between the two diseases, I evaluated the functionality 
of this factor in the small intestine of the three CD mice models described above, upon 
gliadin treatment, by using an ‘ussing chamber’. Surprisingly, we observed an impaired 
CFTR activity in presence of gliadin, paralleled by decreased protein expression, strongly 
indicating a link between gluten intake and CFTR altered activity, typical of CF. Next, it has 
been demonstrated that gliadin is able to directly interact with CFTR driving its degradation. 
Altogether these results support the hypothesis of a link between CD and CF, based on the 
CFTR-gliadin interaction.   
The GI tract is also a complex ecosystem in which the microbiota has been recently 
described as an ‘extra organ’ of the body. It is mainly constituted of bacteria, as well as 
archaea, viruses, protozoa and fungi.  Adult human gastrointestinal tract harbors about 
trillions of bacteria, including at least several hundred species and more than 6000 strains. 
However, this is not an isolated ecosystem but, on the contrary, it is intensely and actively 
connected with the host, via a bidirectional intense communication. Indeed, it plays key roles 
in GI functions such as: microbes facilitate the digestion and transformation of indigestible 
polysaccharides, provide vitamins, participate to the shaping of the intestinal epithelium, are 
involved in host immune defense against pathogens in the intestinal lumen, and contribute 
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to the maintenance of intestinal homeostasis (Lamas et al., 2020). Although the community 
of the GI microbiota does not undergo significant fluctuations throughout adult life, antibiotic 
exposure, infections, lifestyle, and diet might profoundly affect it. Therefore, it is not 
surprising that altered microbiota homeostasis (dysbiosis) has been linked to the 
onset/progression of diseases characterized by inflammation of the GI tract, such as Crohn's 
Disease, Ulcerative Colitis (Yu, 2018) and CD (Chibbar & Dieleman, 2019). Importantly, the 
strong impact of microbiota on host health is not restricted to those pathologies, but has also 
been evidenced in other human diseases ranging from cardiovascular, neurologic, 
respiratory and metabolic illnesses to cancer (Illiano et al., 2020). Nonetheless, buffering the 
gut dysbiosis seems to offer a new treatment opportunity to mitigate, delay, or inhibit the 
progression of several human disorders. Indeed, in this context, a diet supplementation with 
probiotics and prebiotics have been explored as a strategy to modulate the gut microbiome 
to an anti-inflammatory state. In line with these hypotheses, we demonstrated that probiotics 
administration efficiently reduces the hallmarks of intestinal inflammation stimulated by 
gliadin, in our mouse model of CD. 
Significantly, our data show that probiotics, although not interfering with the effects of active 
gliadin peptides on intestinal epithelial CFTR, have a beneficial effect thus inhibiting gut 
inflammation associated with CD. Moreover, our results also indicate a different effect of 
probiotics, at molecular level, depending on the specific formulation. However, further 
studies are required to fully understand the molecular mechanisms by which probiotics 

























The exact mechanisms through which the gluten component gliadin can ignite a stress 
response, responsible for CD onset, are still unclear. Therefore, the identification of in vivo 
models to recapitulate the human disorder is crucial to study the pathogenesis of CD at 
molecular level and to identify new potential treatments.  
During my PhD program, I identified three in vivo pre-clinical model of CD based on: 
• Balb/c mice fed for at least three generation with a gluten-free diet; 
• NOD (non-obese diabetic) mice female, that spontaneous develop diabetes after 12 
weeks of age; 
• NOD DQ8 transgenic mice, expressing HLA-DQ8 in an endogenous MHC class II-
deficient background, which develop diabetes. 
The exposure to gliadin (4 weeks) clearly demonstrated the appearance of typical CD 
markers in all models, as demonstrated by the upregulation of TG2, decreased intestinal 
permeability and production of pro-inflammatory cytokines. Therefore, the selected mice 
models bona fide might be used to study the molecular mechanisms responsible for the 
onset and progression of human CD.  
Indeed, by using these models, it was possible to identify the CFTR as the link between CD 
and CF. In fact, the prevalence of CD observed in CF patients might reside in the impact of 
active gliadin peptides on the activity of epithelial transmembrane CFTR, which in turn 
results in TG2 upregulation, ER stress induction and inflammation. 
Finally, gut dysbiosis has been observed in CD affected patients, although its precise role 
(inducer or consequence) is still unclear. Although further studies are still required to unveil 
the molecular mechanisms, results reported above clearly indicate that rebalancing the gut 
microbiota composition by probiotics administration might represent a new strategy to treat 
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